[1] Dong Y,Lv Q,Li S,et al.Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease:A systematic review and meta-analysis.Clin Res Hepatol Gastroenterol,2017,41:284-295. [2] Ballestri S,Zona S,Targher G,et al.Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incidenttype 2 diabetes and metabolic syndrome.Evidence from a systematic review and meta-analysis.J Gastroenterol Hepatol,2016,31:936-944. [3] Mittal S,El-Serag HB,Sada YH,et al.Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease.Clin Gastroenterol Hepatol,2016,14:124-131. [4] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.中国非酒精性脂肪性肝病诊疗指南(2010年修订版).中国医学前沿杂志(电子版),2012,4:4-10. [5] 余红军,张福生.龙胆泻肝汤联合水飞蓟宾胶囊治疗非酒精性脂肪肝疗效观察.新中医,2017,49:45-47. [6] 孙蓉蓉,李睿,韦维,等.丹田降脂丸联合水飞蓟宾胶囊治疗非酒精性脂肪肝的疗效观察.临床合理用药,2102,5:75-76. [7] 吴茂红,刘太彬,吴晓倩.非诺贝特对糖尿病合并非酒精性脂肪肝患者餐后血脂及血管内皮功能的影响.中国动脉硬化杂志,2013,21:541-544. [8] 李莉,柯柳,韦静彬,等.二甲双胍联合非诺贝特片治疗非酒精性脂肪肝的疗效.广东医学,2018,39:234-236. [9] 郭万越.非酒精性脂肪肝相关因素Logistic回归分析.实用肝脏病杂志,2011,14:376-378. [10] 方林,魏宁,徐浩,等.还原型谷胱甘肽在原发性肝癌介入治疗后保肝作用中的临床应用.介入放射学杂志,2017,26:169-172. [11] 韩怡,胡乃中.还原型谷胱甘肽联合水飞蓟宾治疗肝硬化的临床观察.中国药房,2016,18:1200-1202. [12] 朱戊冲,陈秋通,郭健滨,等.生活方式干预及熊去氧胆酸在非酒精性脂肪肝治疗中的作用.广东医学,2015,36:2415-2417. [13] 朱磊,朱俊岭,钮明杨,等.熊去氧胆酸对婴儿肝炎综合征炎症细胞因子的影响.中国病理生理杂志,2015,31:1142-1144. |